Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Relationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients.

Literature DB >> 23817382

Relationship between trough plasma and epithelial lining fluid concentrations of voriconazole in lung transplant recipients.

Siow-Chin Heng¹, Gregory I Snell, Bronwyn Levvey, Dominic Keating, Glen P Westall, Trevor J Williams, Helen Whitford, Roger L Nation, Monica A Slavin, Orla Morrissey, David C M Kong.

Abstract

Trough (predose) voriconazole concentrations in plasma and pulmonary epithelial lining fluid (ELF) of lung transplant recipients receiving oral voriconazole preemptive treatment were determined. The mean (± standard deviation [SD]) ELF/plasma ratio was 12.5 ± 6.3. A strong positive linear relationship was noted between trough plasma and ELF voriconazole concentrations (r(2) = 0.87), suggesting the feasibility of using trough plasma voriconazole concentration as a surrogate to estimate the corresponding concentration in ELF of lung transplant recipients.

Entities: Chemical

Mesh：

Substances：

Year: 2013 PMID： 23817382 PMCID： PMC3754345 DOI： 10.1128/AAC.00942-13

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

17 in total

1. Antifungal prophylaxis in lung transplantation--a world-wide survey.

Authors: C F Neoh; G I Snell; T Kotsimbos; B Levvey; C O Morrissey; M A Slavin; K Stewart; D C M Kong
Journal: Am J Transplant Date: 2011-01-10 Impact factor: 8.086

2. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.

Authors: F Sabatelli; R Patel; P A Mann; C A Mendrick; C C Norris; R Hare; D Loebenberg; T A Black; P M McNicholas
Journal: Antimicrob Agents Chemother Date: 2006-06 Impact factor: 5.191

3. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome.

Authors: S S Weigt; R M Elashoff; C Huang; A Ardehali; A L Gregson; B Kubak; M C Fishbein; R Saggar; M P Keane; R Saggar; J P Lynch; D A Zisman; D J Ross; J A Belperio
Journal: Am J Transplant Date: 2009-05-13 Impact factor: 8.086

Review 4. Interpretation of antibiotic concentration ratios measured in epithelial lining fluid.

Authors: Sungmin Kiem; Jerome J Schentag
Journal: Antimicrob Agents Chemother Date: 2007-09-10 Impact factor: 5.191

5. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET).

Authors: Peter G Pappas; Barbara D Alexander; David R Andes; Susan Hadley; Carol A Kauffman; Alison Freifeld; Elias J Anaissie; Lisa M Brumble; Loreen Herwaldt; James Ito; Dimitrios P Kontoyiannis; G Marshall Lyon; Kieren A Marr; Vicki A Morrison; Benjamin J Park; Thomas F Patterson; Trish M Perl; Robert A Oster; Mindy G Schuster; Randall Walker; Thomas J Walsh; Kathleen A Wannemuehler; Tom M Chiller
Journal: Clin Infect Dis Date: 2010-04-15 Impact factor: 9.079

6. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections.

Authors: Andres Pascual; Chantal Csajka; Thierry Buclin; Saskia Bolay; Jacques Bille; Thierry Calandra; Oscar Marchetti
Journal: Clin Infect Dis Date: 2012-05-18 Impact factor: 9.079

7. Prospective, observational study of voriconazole therapeutic drug monitoring among lung transplant recipients receiving prophylaxis: factors impacting levels of and associations between serum troughs, efficacy, and toxicity.

Authors: Dimitra Mitsani; M Hong Nguyen; Ryan K Shields; Yoshiya Toyoda; Eun J Kwak; Fernanda P Silveira; Joseph M Pilewski; Maria M Crespo; Christian Bermudez; Jay K Bhama; Cornelius J Clancy
Journal: Antimicrob Agents Chemother Date: 2012-02-13 Impact factor: 5.191

8. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults.

Authors: Jared L Crandon; Mary Anne Banevicius; Annie F Fang; Penelope H Crownover; R Fredrick Knauft; J Samuel Pope; John H Russomanno; Eric Shore; David P Nicolau; Joseph L Kuti
Journal: Antimicrob Agents Chemother Date: 2009-09-21 Impact factor: 5.191

Review 9. Antifungal pharmacokinetics and pharmacodynamics: bridging from the bench to bedside.

Authors: W W Hope; G L Drusano
Journal: Clin Microbiol Infect Date: 2009-07 Impact factor: 8.067

10. Bioavailability and population pharmacokinetics of voriconazole in lung transplant recipients.

Authors: Kelong Han; B Capitano; R Bies; B A Potoski; S Husain; S Gilbert; D L Paterson; K McCurry; R Venkataramanan
Journal: Antimicrob Agents Chemother Date: 2010-08-02 Impact factor: 5.191

5 in total

Review 1. Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.

Authors: Haiying Jin; Tiansheng Wang; Bonnie A Falcione; Keith M Olsen; Ken Chen; Huilin Tang; John Hui; Suodi Zhai
Journal: J Antimicrob Chemother Date: 2016-03-10 Impact factor: 5.790

2. A strategy for designing voriconazole dosage regimens to prevent invasive pulmonary aspergillosis based on a cellular pharmacokinetics/pharmacodynamics model.

Authors: Taotao Wang; Tao Zhang; Ti Meng; Ying Li; Lu Chen; Qianting Yang; Haiyan Dong; Jin'e Lei; Limei Chen; Yalin Dong
Journal: J Transl Med Date: 2018-06-07 Impact factor: 5.531